Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

Lentiviral-Mediated Gene Therapy for Patients with Fanconi Anemia [Group a]: Updated Results from Global RP-L102 Clinical Trials

Blood (2024) 144 (Supplement 1): 7463.

https://doi.org/10.1182/blood-2024-194638

Published: 2024

Journal Articles

Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy Manufactured Using a Next-Generation Process, for Severe, Refractory Autoimmune Diseases: Updated Data from Ongoing Phase 1, Multicenter, Open-Label Studies

Blood (2024) 144 (Supplement 1): 2088.

https://doi.org/10.1182/blood-2024-194525

Published: 2024

Journal Articles

Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis

Blood (2024) 144 (Supplement 1): 3794.

https://doi.org/10.1182/blood-2024-194857

Published: 2024

Journal Articles

Dose of Venetoclax in Combination with Hypomethylating Agents and Outcomes of Patients with Acute Myeloid Leukemia: A Retrospective Study

Farah Yassine, Firas Saad, Mahija Cheekati, John Rutledge, Brian Baksa, Mohamad Cherry

Blood (2024) 144 (Supplement 1): 2884.

https://doi.org/10.1182/blood-2024-194499

Published: 2024

Journal Articles

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Blood (2023) 142 (Supplement 1): 5953.

https://doi.org/10.1182/blood-2023-181151

Published: 2023

Journal Articles

Anemia Outside the Box: Nonimmune Intramedullary Hemolytic Anemia Driven By Vitamin B12 Deficiency

Farah Yassine, Mostafa Naguib, Mahija Cheekati, Geoffrey Nasuti, Megha Chiruvella, Mohamad A. Cherry

Blood (2023) 142 (Supplement 1): 5198.

https://doi.org/10.1182/blood-2023-179699

Published: 2023

Journal Articles

Evaluating the Effectiveness of COVID-19 Vaccines in Adults with Sickle Cell Disease during the Omicron Period of COVID-19 Pandemic

Blood (2023) 142 (Supplement 1): 1149.

https://doi.org/10.1182/blood-2023-185320

Published: 2023

Journal Articles

A Fatal Case of Hemophagocytic Lymphohistiocytosis Triggered By Babesiosis

Mahija Cheekati, Matthew Knapp, Farah Yassine, Megha Chiruvella, Mohamad A. Cherry

Blood (2023) 142 (Supplement 1): 5387.

https://doi.org/10.1182/blood-2023-181759

Published: 2023

Journal Articles

Risk and Protective Factors for COVID-19 Infection Among Pregnant Women with Sickle Cell Trait

Kim Abbegail Tan Aldecoa, Camelia Arsene, Tiffany Chng, Garett Cherry, Nabila Chowdhury, Ryan Clark, Dana Deeb, Lisa Deptula, Grey Dietz, Ewomamobuho Eto, Victoria Golston, Landon Lawson, Chioma Mbionwu, Obiefuna Okponyia, Jennifer Orejuela, Thomaida Qipo, Sumit Raut, Geetha Krishnamoorthy, Judie Goodman

Blood (2023) 142 (Supplement 1): 5295.

https://doi.org/10.1182/blood-2023-185167

Published: 2023

Journal Articles

A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Aaron D Goldberg, Maro Ohanian, Paul B. Koller, Mohamad Cherry, Jessica K. Altman, Benjamin Tomlinson, Namrata Sonia Chandhok, Donna Nguyen Haney, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar

Blood (2022) 140 (Supplement 1): 6220–6221.

https://doi.org/10.1182/blood-2022-167759

Published: 2022

Journal Articles

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Blood (2022) 140 (Supplement 1): 6498–6500.

https://doi.org/10.1182/blood-2022-163683

Published: 2022

Journal Articles

Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

Suman Kambhampati, Christine M. McMahon, Alireza Eghtedar, Daniel A. Pollyea, Stephane de Botton, Arnaud Pigneux, Mohamad Cherry, Brian J Ball, Gautam Borthakur, Thomas Cluzeau, Gary J. Schiller, Beibei Hu, Angela Volkert, Joanie Aasen Gausman, Graeme Hodgson, David A. Roth, Erica D. Warlick, Michael J. Kelly, Eytan Stein

Blood (2022) 140 (Supplement 1): 3333–3335.

https://doi.org/10.1182/blood-2022-156564

Published: 2022

Journal Articles

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Yuliya Linhares, Cesar Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris, Daanish Hoda, Juan Carlos Varela, Courtney Bellomo, Scott Cross, James Essell, Suzanne Fanning, Howard Terebelo, Habte Yimer, Jay Courtright, Jeff P. Sharman, Min Vedal, Connor Mailley, Ricardo Espinola, Bassam Mattar

Blood (2022) 140 (Supplement 1): 10416–10418.

https://doi.org/10.1182/blood-2022-159595

Published: 2022

Journal Articles

A Study to Evaluate the Utility and Appropriateness of Diagnostic Workup for Leukocytosis in the Hematology Clinic

Megan Randall, Chen Zhang, Matthew Kroll, Kelsey Pandrangi, Gautham Prakash, Cherry Au, Ashley Dunton, Yanyu Zhang, Melissa L. Larson, Jamile M. Shammo

Blood (2022) 140 (Supplement 1): 12288–12289.

https://doi.org/10.1182/blood-2022-167402

Published: 2022

Journal Articles

Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study

Yuliya Linhares, Fei Fei Liu, Cesar Freytes, Mohamad Cherry, Ling Shi, Weiqin Liao, Julia Braverman, Ricardo Espinola, Min Vedal, Bassam Mattar

Blood (2022) 140 (Supplement 1): 10930–10931.

https://doi.org/10.1182/blood-2022-159645

Published: 2022

Journal Articles

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Aaron D Goldberg, Maro Ohanian, Paul Koller, Jessica K. Altman, Mohamad Cherry, Benjamin Tomlinson, Namrata Chandhok, Hongying Zhang, Nasrin Rastgoo, Khalid Benbatoul, Yuying Jin, Genia Su, Jotin Marango, Stephen B Howell, William G Rice, Rafael Bejar

Blood (2021) 138 (Supplement 1): 1272.

https://doi.org/10.1182/blood-2021-149333

Published: 2021

Journal Articles

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

John E. Godwin, Bassam Mattar, Michael Maris, Carlos Bachier, Don Stevens, Daanish Hoda, Juan C. Varela, Mohamad Cherry, Suzanne Fanning, James Essell, Habte Yimer, Jay Courtright, Jeff P. Sharman, Ricardo Espinola, Connor Mailley, Ariel Avilion, Ken Ogasawara, San-San Ou, Paul Shaughnessy

Blood (2021) 138 (Supplement 1): 1762.

https://doi.org/10.1182/blood-2021-148792

Published: 2021

Journal Articles

Clinical Outcomes of COVID-19 Infection Among Children with Cancer: A Single-Center Experience

Esra Akkoyun, Jesus Sotelo, Giselle Cherry, Maria Bisceglia, Tamra Slone, Victor Aquino, Paul Sue

Blood (2021) 138 (Supplement 1): 3366.

https://doi.org/10.1182/blood-2021-153966

Published: 2021

Journal Articles

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

Blood (2021) 138 (Supplement 1): 1355.

https://doi.org/10.1182/blood-2021-148827

Published: 2021

Journal Articles

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Keith W. Pratz, MD, Mohamad Cherry, MDMS, Jessica K. Altman, MD, Brenda W. Cooper, MD, Jose Carlos Cruz, MD, Joseph G. Jurcic, MD, Mark Levis, MD PhD, Tara Lin, MD, Alexander E. Perl, MD, Nikolai A. Podoltsev, MD PhD, Gary J. Schiller, MD, Jason E. Hill, PhD, Angela James, PhD, Qiaoyang Lu, MS, Ramon V. Tiu, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-137685

Published: 2020

NARROW

Lentiviral-Mediated Gene Therapy for Patients with Fanconi Anemia [Group a]: Updated Results from Global RP-L102 Clinical Trials

Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis

Dose of Venetoclax in Combination with Hypomethylating Agents and Outcomes of Patients with Acute Myeloid Leukemia: A Retrospective Study

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Anemia Outside the Box: Nonimmune Intramedullary Hemolytic Anemia Driven By Vitamin B12 Deficiency

Evaluating the Effectiveness of COVID-19 Vaccines in Adults with Sickle Cell Disease during the Omicron Period of COVID-19 Pandemic

A Fatal Case of Hemophagocytic Lymphohistiocytosis Triggered By Babesiosis

Risk and Protective Factors for COVID-19 Infection Among Pregnant Women with Sickle Cell Trait

A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1a/b Dose Escalation Study of the BTK/FLT3 Inhibitor Luxeptinib in Patients with Relapsed or Refractory B-Cell Malignancies

Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

Results from Outreach: A Phase 2 Study of Lisocabtagene Maraleucel (Liso-cel) Administered As Outpatient (Outpt) or Inpatient (Inpt) Treatment in the Community/Nonuniversity Setting in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

A Study to Evaluate the Utility and Appropriateness of Diagnostic Workup for Leukocytosis in the Hematology Clinic

Lisocabtagene Maraleucel (Liso-cel) in Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Treated As Outpatients or Inpatients in the Community/Nonuniversity Setting: Patient-Reported Outcomes/Health-Related Quality of Life from the Outreach Study

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Outreach: Results from a Phase 2 Study of Lisocabtagene Maraleucel (liso-cel) Administered As Inpatient (Inpt) or Outpatient (Outpt) Treatment in the Nonuniversity Setting in Patients (Pts) with R/R Large B-Cell Lymphoma (LBCL)

Clinical Outcomes of COVID-19 Infection Among Children with Cancer: A Single-Center Experience

A Phase 1a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory B-Cell Malignancies

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only